Envista Holdings Corp (NVST) company profile
Close on Nov 16, 2026Market cap $3.86BP/E 41.4Yield –
About Envista
Dental Equipment & Supplies, SIC 3843
Envista develops, manufactures, and markets dental products, equipment, and software solutions worldwide. The company operates through two segments: Specialty Products & Technologies, and Equipment & Consumables. Its portfolio includes dental implant systems, regenerative solutions, prosthetics, orthodontic brackets and wires, clear aligners, digital imaging systems, endodontic and restorative materials, rotary burs, and infection prevention products. Envista serves dental specialists—including orthodontists, periodontists, implantologists, endodontists, and oral surgeons—as well as general dentists, dental hygienists, dental laboratories, dental service organizations, and distributors.
The company employs approximately 12,000 individuals, with roughly 3,000 in the United States and 9,000 internationally. Envista serves dental professionals across more than 130 countries, conducting business in North America, Western Europe, and various emerging and developed markets. It conducts research and development activities primarily in North America, the Middle East, and Europe. The provided text mentions no headquarters location.
Summary of the business section of Envista's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Envista Holdings Corp
- Founded
- 2018
- Headquarters
- Brea, CA
- Address
- 200 S. Kraemer Blvd., Bldg. E 92821
- Phone
- (714) 817-5418
- Website
- envistaco.com
- Employees
- 12,000, Dec 31, 2025
- Industry
- Dental Equipment & Supplies
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, Irvine, California
Stock & identifiers
- Ticker
- NVST
- Exchange
- NYSE
- IPO date
- Sep 19, 2019
- Shares outstanding
- 161M, Jul 31, 2026
- Public float
- $2.50B, Jun 27, 2025
- Filer category
- Large accelerated filer
- SEC CIK
- 1757073
- CUSIP
- 29415F104
- ISIN
- US29415F1049
- FIGI
- BBG00LN4B5N0
- Share class FIGI
- BBG00LN4B6D9
- LEI
- 549300BX623VURJZ5269
- EIN
- 83-2206728
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Paul A. Keel | Chairman and CEO, Director | 497,107 |
| Robert Befidi | President, Diagnostics | 45,785 |
| Veronica Acurio | President, Orthodontics | 48,806 |
| Eric D. Hammes | Chief Financial Officer | 99,913 |
| Stefan Nilsson | President, Nobel Biocare | 61,560 |
| Mischa Reis | SVP, Strategy & Bus. Dev. | 27,321 |
| Coree K. Thomas | CAO | 2,535 |
| Faez C. Kaabi | Chief Accounting Officer | 58,552 |
| Mark E. Nance | General Counsel | 68,577 |
| Daniel Raskas | Director | 54,010 |
| Christine A. Tsingos | Director | 59,930 |
| Vivek Jain | Director | 52,945 |
| Wendy Carruthers | Director | 59,940 |
| R. Scott Huennekens | Director | 82,105 |
| Kieran Gallahue | Director | 54,010 |
| James Andrew Pierce | Director | 18,485 |
| Barbara B. Hulit | Director | 79,820 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $10.56M | $14.25M | $2.35M | $64 | $136 |
| FY2024 Amir Aghdaei | $8.92M | $4.21M | $2.37M | $57 | $121 |
| FY2024 Paul Keel | $23.83M | $22.80M | $2.37M | $57 | $121 |
| FY2023 | $7.06M | -$1.82M | $1.68M | $71 | $120 |
| FY2022 | $8.52M | -$4.54M | $1.84M | $100 | $120 |
| FY2021 | $9.20M | $28.84M | $2.47M | $134 | $124 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Stock awards | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|
| Paul Keel President & CEO | $1.10M | $5.44M | $1.36M | $2.49M | $172.82K | $10.56M | -56% |
| Eric Hammes Chief Financial Officer | $592.31K | $975.15K | $325.01K | $739.80K | $13.70K | $2.65M | -7% |
| Mark Nance SVP and General Counsel | $559.62K | $1.13M | $375.02K | $551.43K | $33.99K | $2.65M | -15% |
| Veronica Acurio President, Orthodontics | $550.00K | $637.67K | $212.51K | $720.72K | $52.20K | $2.17M | – |
| Robert Befidi President, Diagnostics | $567.31K | $637.67K | $212.51K | $470.93K | $47.85K | $1.94M | -16% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Sep 19, 2019
- Offer price
- $22.00
- Securities offered
- 26,768,000
- Gross proceeds
- $588.90M
- Exchange
- NYSE
- Lock-up ends (est.)
- Mar 17, 2020
“The initial public offering price is $22.00 per share of common stock.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we employed approximately 12,000 persons, of whom approximately 3,000 were employed in the U.S.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jun 16, 2021 | Deregistration | Termination of SEC registration (Form 15) |
| Nov 15, 2019 | Merger | Registration of securities for a merger or exchange offer (S-4) |
| Sep 19, 2019 | IPO | Initial public offering priced (424B4 prospectus) |
| Sep 17, 2019 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?